ILKOS THERAPEUTIC INC. is a biotechnology firm created in Laval (Quebec) in September 2016, following a strategic alliance between CTI Life Sciences Fund, Servier and Fonds de solidarité FTQ , all three equal partners.
ILKOS THERAPEUTIC INC. obtained a worldwide and exclusive licence from Servier for its novel compound, S42909, indicated for the oral treatment of venous lower limb ulcers.
The vision of ILKOS THERAPEUTIC INC. is to make a difference in the lives of patients suffering from venous lower limb ulcers, a disease that affects 1% to 1.5% of the population, mainly older people, by offering them the first disease-modifying oral treatment. This represents a potential clinical breakthrough.
The mission of ILKOS THERAPEUTIC INC. is to demonstrate the efficacy and safety of S42909 in a Phase 2a multicentre clinical study conducted in North America and Europe and involving more than 200 patients.
Excellence in execution